Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Clinical trial NCT07008976 · RECRUITING

Trial details

NCT number: NCT07008976
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2025-07-07
Primary completion: 2028-03-01
Enrollment: 246

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.